Osteopenia and decreased bone formation in osteonectin-deficient mice

Journal of Clinical Investigation

Volumn 105, Issue 7, 2000, Pages 915-923

  Delany, A M ^a,b   Amling, M ^c   Priemel, M ^c   Howe, C ^d   Baron, R ^e   Canalis, E ^a  

^a SAINT FRANCIS HOSPITAL AND MEDICAL CENTER   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF HAMBURG   (Germany)

^d WISTAR INSTITUTE   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; OSTEONECTIN; SCLEROPROTEIN;

ANIMAL EXPERIMENT; ARTICLE; BONE MASS; BONE REMODELING; CONTROLLED STUDY; MOUSE; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOGENESIS IMPERFECTA; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION;

EID: 0034129090     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI7039     Document Type: Article

References (55)

1. Margolis, R.N., Canalis, E., and Partridge, N.C. 1996. Anabolic hormones in bone: basic research and therapeutic potential. J. Clin. Endocrinol. Metab. 81:872-877.
2. Baron, R.E. 1996. Anatomy and ultrastructure of bone. In Primer on the metabolic bone diseases and disorders of mineral metabolism. M.J. Favus, editor. Lippincott-Raven Publishers. New York, NY. 3-10.
3. Keen, R.W., and Kelly, P.J. 1997. Genetic factors in osteoporosis. What are the implications for prevention and treatment? Drugs Aging. 11:333-337.
4. Corral, D., et al. 1998. Dissociation between bone resorption and bone formation in osteopenic transgenic mice. Proc. Natl. Acd. Sci., USA. 95:13835-13840.
5. Young, M.F., Kerr, J.M., Ibaraki, K., Heegaard, A.M., and Gehron Robey, P. 1992. Structure, expression, and regulation of the major noncollagenous matrix proteins of bone. Clin. Orthop. 281:275-294.
6. Lane, T.F., and Sage, E.H. 1994. The biology of SPARC, a protein that modulated cell-matrix interactions. FASEB J. 8:163-173.
7. Shankavaram, U.T., DeWitt, D.L., Funk, S.E., Sage, E.H., and Wahl, L.M. 1997. Regulation of human monocyte matrix metalloproteinases by SPARC. J. Cell. Physiol. 173:327-334.
8. Tremble, P.M., Lane, T.F., Sage, E.H., and Werb, Z. 1993. SPARC, a secreted protein associated with morphogenesis and tissue remodeling, induces expression of metalloproteinases in fibroblasts through a novel extracellular matrix-dependent pathway. J. Cell Biol. 121:1433-1444.
9. Wrana, J.L., et al. 1988. Differential effects of transforming growth factor-b on the synthesis of extracellular matrix proteins by normal fetal rat calvarial bone cell populations. J. Cell Biol. 106:915-924.
10. Nakamura, S., et al. 1996. Enhancement of SPARC (osteonectin) synthesis in arthritic cartilage. Increased levels in synovial fluids from patients with rheumatoid arthritis and regulation by growth factors and cytokines in chondrocyte cultures. Arthritis Rheum. 39:539-551.
11. Delany, A.M., and Canalis, E. 1998. Basic fibroblast growth factor destabilizes osteonectin mRNA in osteoblasts. Am. J. Physiol. 274:C734-C740.
12. Ng, K.W., Manji, S.S., Young, M.F., and Findlay, D.M. 1989. Opposing influences of glucocorticoid and retinoic acid on transcriptional control in preosteoblasts. Mol. Endocrinol. 3:2079-2085.
13. Muriel, M.P., et al. 1991. Morphological and biochemical studies of a mouse mutant (fro/fro) with bone fragility. Bone. 12:241-248.
14. Fedarko, N.S., Gehron Robey, P., and Vetter, U.K. 1995. Extracellular matrix stoichiometry in osteoblasts from patients with osteogenesis imperfecta. J. Bone Miner. Res. 10:1122-1129.
15. Fisher, L.W., Drum, M.A., Gehron Robey, P., Conn, K.M., and Termine, J.D. 1987. Osteonectin content in human osteogenesis imperfecta bone shows a range similar to that of two bovine models of OI. Calcif Tissue Int. 40:260-264.
16. Norose, K., et al. 1998. SPARC deficiency leads to early onset cataractogenesis. Invest. Ophthalmol. Vis. Sci. 39:2674-2680.
17. Gilmour, D.T., et al. 1998. Mice deficient for the secreted glycoprotein SPARC/osteonectin/BM40 develop normally but show severe age-onset cataract formation and disruption of the lens. EMBO J. 17:1860-1870.
18. Amling, M., et al. 1997. Bcl-2 lies downstream of parathyroid hormone-related peptide in a signaling pathway that regulates chondrocyte maturation during skeletal development. J. Cell Biol. 136:205-213.
19. Parfitt, A.M., et al 1987. Bone histomorphometry: standardization of nomenclature, symbols and units. J. Bone Miner. Res. 6:595-610.
20. Baron, R., Tross, R., and Vignery, A. 1984. Evidence of sequential remodeling in rat trabecular bone: morphology, dynamic histomorphometry, and changes during skeletal maturation. Anat. Rec. 208:137-145.
21. Amling, M., et al. 1999. Rescue of the skeletal phenotype of vitamin D receptor ablated mice in the setting of normal mineral ion homeostasis: formal histomorphometric and biomechanical analysis. Endocrinology. 140:4982-4987.
22. Chomczynski, P., and Sacchi, N. 1987. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:156-159.
23. Quinn, C.O., et al. 1990. Rat collagenase: cloning, amino acid sequence comparison, and parathyroid hormone regulation in osteoblastic cells. J. Biol. Chem. 265:22342-22347.
24. Bolander, M.E., Young, M.F., Fisher, L.W., Yamada, Y., and Termine, J.D. 1988. Osteonectin cDNA sequence reveals potential binding regions for calcium and hydroxyapatite and shows homologies with both a basement membrane protein (SPARC) and a serine proteinase inhibitor (ovomucoid). Proc. Natl. Acad. Sci. USA. 85:2919-2923.
25. Young, M.F., Ibaraki, K., Kerr, J.M., Lyu, M.S., and Kozak, C.A. 1994. Murine bone sialoprotein (BSP): cDNA cloning, mRNA expression, and generic mapping. Mamm. Genome. 5:108-111.
26. Schwarzbauer, J.E., Tamkun, J.W., Lemischka, I.R., and Hynes, R.O. 1983. Three different fibronectin mRNAs arise by alternative splicing within the coding region. Cell. 35:421-431.
27. Lian, J., et al. 1989. Structure of the rat osteocalcin gene and regulation of vitamin D-dependent expression. Proc. Natl. Acad. Sci. USA. 86:1143-1147.
28. Masure, S., Nys, G., Fiten, P., Van Damme, J., and Opdenakker, G. 1993. Mouse gelatinase B. cDNA cloning, regulation of expression and glycosylation in WEHI+3 macrophages and gene organization. Eur. J. Biochem. 218:129-141.
29. Levy, A.T., et al. 1991. Increased expression of the Mr 72,000 type IV collagenase in human colonic adenocarcinoma. Cancer Res. 51:439-444.
30. 2 collagen mRNA and their use in studying the regulation of type I collagen synthesis by 1,25-dihydroxyvitamin D. Biochemistry. 23:6210-6216.
31. Tso, J.Y., Sun, X.H., Kau, T.-H., Reece, K.S., and Wu, R. 1985. Isolation and characterization of rat and human glyceraldehyde-3-phosphate dehydrogenase cDNAs: genomic complexity and molecular evaluation of the gene. Nucleic Acids Res. 13:2485-2502.
32. Lennon, G., Auffray, C., Polymeropoulos, M., and Soates, M.B. 1996. The I.M.A.G.E. consortium: an integrated molecular analysis of genomes and their expression. Genomics. 33:151-152.
33. Gundberg, C.M., Hauschka, P.V., Lian, J.B., and Gallop, P.M. 1984. Osteocalcin: isolation, characterization, and detection. Methods Enzymol. 107:516-544.
34. Kimble, R.B., et al. 1994. Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats. J. Clin. Invest. 93:1959-1967.
35. Recker, R.R. 1996. Bone remodeling abnormalities in osteoporosis. In Osteoporosis. R. Marcus, O. Feldman, and J. Kelsey, editors. Academic Press. San Diego, CA. 703-713.
36. Khosla, S., and Kleerekoper, M. 1999. Biochemical markers of bone turnover. In Primer on the metabolic bone diseases and disorders of mineral metabolism. M.H.J. Flavus, editor. Lippincott Williams and Wilkins. Philadelphia, PA. 128-134.
37. Rifas, L., Fausto, A., Scott, M.J., Avioli, L.V., and Welgus, H.G. 1994. Expression of metalloproteinases and tissue inhibitors of metalloproteinases in human osteoblast-like cells: differentiation is associated with repression of metalloproteinase synthesis. Endocrinology. 134:213-221.
38. Lorenzo, J.A., Pilbeam, C.C., Kalinowski, J.F., and Hibbs, M.S. 1992. Production of both 92- and 72-kDa gelatinases by bone cells. Matrix. 12:282-290.
39. Delany, A.M., and Canalis, H. 1998. Dual regulation of stromelysin-3 by fibroblast growth factor-2 in murine osteoblasts. J. Biol. Chem. 273:16595-16600.
40. Tezuka, K., et al. 1994. Identification of matrix metalloproteinase 9 in rabbit osteoclasts. J. Biol. Chem. 269:15006-15009.
41. Sato, T., et al. 1997. Identification of the membrane-type matrix metalloproteinase MT1-MMP in osteoclasts. J. Cell Sci. 110:589-596.
42. Vu, T.H., et al. 1998. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes. Cell. 93:411-422.
43. Gerber, H.P., et al. 1999. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation. Nat. Med. 5:623-628.
44. Wang, D.S., Miura, M. Demura, H., and Saro, K. 1997. Anabolic effects of 1,25-dihydroxyvitamin D3 on osteoblasts are enhanced by vascular endothelial growth factor produced by osteoblasts and by growth factors produced by endothelial cells. Endocrinology. 138:2953-2962.
45. Ninomiya, J.T., et al. 1990. Heterogeneity of human bone. J. Bone Miner. Res. 5:933-938.
46. Delmas, P.D. 1990. Biochemical markers of bone turnover for the clinical assessment of metabolic disease. Endocrinol. Metab. Clin. North Am. 19:1-18.
47. Jodar Gimeno, E., et al. 1997. Identification of metabolic bone disease in patients with endogenous hyperthyroidism: role of biological markers of bone turnover. Calcif. Tissue Int. 61:370-376.
48. Beamer, W.G., et al. 1996. Genetic variability in adult bone density among inbred strains of mice. Bone. 18:397-403.
49. Boskey, A., Spevak, L., Amling, M., Canalis, E., and Delany, A. 2000. Mineral analysis of osteonectin-deficient mouse bones confirms altered remodeling activity. Transactions of the Orthopedic Research Society. 26:135. http://www.ors.org
50. Soderling, J.A., Reed, M.J., Corsa, A., and Sage, E.H. 1997. Cloning and expression of murine SC1, a gene product homologous to SPARC. J. Histochem. Cytochem. 45:823-835.
51. Shima, D.T., et al. 1996. The mouse gene for vascular endothelial growth factor: genomic structure, definition of the transcriptional unit, and characterization of transcriptional and post-transcriptional regulatory sequences. J. Biol. Chem. 271:3877-3883.
52. Neufeld, G., Cohen, T., Gengrinovitch, S., and Poltorak, Z. 1999. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13:9-22.
53. Ducy, P., et al. 1996. Increased bone formation in osteocalcin-deficient mice. Nature. 382:448-452.
54. Xu, T., et al. 1998. Targeted disruption of the biglycan gene leads to an osteoporosis-like phenotype in mice. Nat. Genet. 20:78-82.
55. Kassem, M., Melton, L.J., III, and Riggs, B.L. 1996. The type I/type II model for involutional osteoporosis. In Osteoporosis. R. Marcus, D. Feldman, and J. Kelsey, editors. Academic Press, San Diego, CA. 703-713.